| 规格 | 价格 | 库存 |
|---|---|---|
| 10µg | ¥ 4428 | 1 |
Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis and the oligomer sequence is confirmed by sequencing. TotalSeq?-C antibodies are compatible with 10x Genomics Chromium Single Cell Immune Profiling Solution.
To maximize performance, it is strongly recommended that the reagent be titrated for each application, and that you centrifuge the antibody dilution before adding to the cells at 14,000xg at 2 - 8°C for 10 minutes. Carefully pipette out the liquid avoiding the bottom of the tube and add to the cell suspension. For Proteogenomics analysis, the suggested starting amount of this reagent for titration is ≤ 1.0 ?g per million cells in 100 ?L volume. Refer to the corresponding TotalSeq? protocol for specific staining instructions.
For successful staining of human cells, brighter fluorophore-antibody conjugates, such as PE, BV421?, or APC, are recommended.
Additional reported applications (for relevant formats) include: Western Blotting1.
TotalSeq? reagents are designed to profile protein levels at a single cell level following an optimized protocol similar to the CITE-seq workflow. A compatible single cell device (e.g. 10x Genomics Chromium System and Reagents) and sequencer (e.g. Illumina analyzers) are required. Please contact technical support for more information, or visit biolegend.com/totalseq.
The barcode flanking sequences are CGGAGATGTGTATAAGAGACAGNNNNNNNNNN (PCR handle), and NNNNNNNNNCCCATATAAGA*A*A (capture sequence). N represents either randomly selected A, C, G, or T, and * indicates a phosphorothioated bond, to prevent nuclease degradation.
View more applications data for this product in our Scientific Poster Library.
This product may be used for research purposes only.? It is not licensed for resale and may only be used by the buyer.? This product may not be used and is not licensed for clinical assays, where the results of such assays are provided as a diagnostic service.? If a diagnostic or therapeutic use is anticipated, then a license must be requested from the University of California.? The availability of such diagnostic and therapeutic use license(s) cannot be guaranteed from the University of California.
Subsets of NK cells, lymphokine-activated killer (LAK) cells and subsets of CD8+ and CD4+ cells.
1. Grundemann C, et al. 2006. J. Immunol. 176:1311.
2. Blaser C, et al. 1998. J. Immunol. 161:6451.
3. Huntington ND, et al. 2007. J. Immunol. 178:4764.
4. Voehringer D, et al. 2001. J. Immunol. 167:4834.